GlaxoSmithKline (GSK) Receives “Overweight” Rating from Barclays

Barclays restated their overweight rating on shares of GlaxoSmithKline (LON:GSK) in a research note issued to investors on Friday.

Several other brokerages have also recently commented on GSK. Goldman Sachs Group set a GBX 1,900 ($24.83) target price on GlaxoSmithKline and gave the stock a buy rating in a report on Wednesday. Deutsche Bank set a GBX 1,525 ($19.93) target price on GlaxoSmithKline and gave the stock a neutral rating in a report on Tuesday, July 31st. Liberum Capital reissued a buy rating on shares of GlaxoSmithKline in a report on Monday, July 23rd. Societe Generale set a GBX 1,000 ($13.07) target price on GlaxoSmithKline and gave the stock a sell rating in a report on Monday, September 10th. Finally, JPMorgan Chase & Co. set a GBX 1,600 ($20.91) target price on GlaxoSmithKline and gave the stock a neutral rating in a report on Tuesday, September 18th. One analyst has rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus target price of GBX 1,521.27 ($19.88).

LON:GSK traded down GBX 32.20 ($0.42) during midday trading on Friday, hitting GBX 1,480 ($19.34). 10,492,086 shares of the stock were exchanged, compared to its average volume of 9,120,000. GlaxoSmithKline has a one year low of GBX 1,235.20 ($16.14) and a one year high of GBX 1,724.50 ($22.53).

The company also recently disclosed a dividend, which will be paid on Thursday, January 10th. Shareholders of record on Thursday, November 15th will be given a dividend of GBX 19 ($0.25) per share. This represents a yield of 1.26%. The ex-dividend date of this dividend is Thursday, November 15th.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Recommended Story: Cash Flow

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply